Cited by 234Bone Metabolism and DiseasesProstate Cancer Treatment and ResearchBone health and treatments

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Osteoprotegerin and RANK ligand expression in prostate cancer.

Brown, Julie M, Corey, Eva, Lee, Zandra D, True, Lawrence D, Yun, Theodore J, Tondravi, Mehrdad, Vessella, Robert L·2001·Urology

DOI 10.1016/s0090-4295(00)01122-5

Open this paper in CoChat — free account

Abstract

Objectives To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Methods Tissues from 28 patients with CaP and from 4 normal organ donors were analyzed by reverse transcriptase-polymerase chain reaction and immunohistochemistry for the expression of OPG and RANKL.Results OPG and RANKL messages were detected in both normal and cancerous prostate samples. In the normal prostate, OPG protein was detected in luminal epithelial and stromal cells (5% to 65% and 15% to 70%, respectively) and RANKL immunoreactivity was observed in 15% to 50% of basal epithelial cells, 40% to 90% of luminal epithelial cells, and 70% to 100% of stromal cells. OPG was not detected in 8 of 10 primary CaP specimens; RANKL was heterogeneously expressed in 10 of 11 CaP specimens. The percentage of tumor cells expressing OPG and RANKL was significantly increased in all CaP bone metastases compared with nonosseous metastases or primary CaP.Conclusions CaP bone metastases were consistently immunoreactive for both OPG and RANKL compared with nonosseous metastases or primary CaP. The presence of these crucial bone resorption regulators in CaP bone metastases suggests a mechanism whereby CaP cells may modulate bone turnover and has profound implications for the establishment and development of CaP bone metastases in advanced disease.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(00)01122-5

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-602
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650
Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00162-3 · Cited by 630
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
Honoré, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L. R., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 497

Show all 18 references

Sorted by citations

IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology
Tat, S. K., Marc, P., Théoleyre, S., Heymann, D., & Fortun, Y. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2003.10.005 · Cited by 990
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 777
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martín, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 698
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Chronic Inflammation in Cancer Development
Multhoff, G., Molls, M., & Radons, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00098 · Cited by 614
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Lynch, C. C., Hikosaka, A., Acuff, H. B., Martin, M. D., Kawai, N., Singh, R. K., Vargo-Gogola, T. C., Begtrup, J. L., Peterson, T. E., Fingleton, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.013 · Cited by 402
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
Keller, E. T., & Brown, J. K. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10662 · Cited by 298
Self-citation
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions
Akech, J., Wixted, J. J., Bedard, K., van der Deen, M., Hussain, S., Guise, T. A., van Wijnen, A. J., Stein, J. L., Languino, L. R., Altieri, D. C., et al. (2009) · Oncogene · doi:10.1038/onc.2009.389 · Cited by 302
Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. (2002) · PubMed · Cited by 270
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis
Wittrant, Y., Théoleyre, S., Chipoy, C., Padrines, M., Blanchard, F., Heymann, D., & Rédiní, F. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.05.002 · Cited by 238
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
Chen, G., Sircar, K., Aprikian, A. G., Potti, A., Goltzman, D., & Rabbani, S. A. (2006) · Cancer · doi:10.1002/cncr.21978 · Cited by 229
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications
Jung, K., Lein, M., Stephan, C., von Hößlin, K., Semjonow, A., Sinha, P. K., Loening, S. A., & Schnorr, D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20314 · Cited by 225
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer
Tsukamoto, S., Ishikawa, T., Iida, S., Ishiguro, M., Mogushi, K., Mizushima, H., Uetake, H., Tanaka, H., & Sugihara, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2884 · Cited by 210
Molecular mechanisms and clinical management of cancer bone metastasis
Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 204
Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells
Corey, E., Quinn, J. E., Bladou, F., Brown, L. G., Roudier, M. P., Brown, J. M., Buhler, K. R., & Vessella, R. L. (2002) · The Prostate · doi:10.1002/pros.10091 · Cited by 193
Self-citation
The RANK/RANKL/OPG triad in cancer-induced bone diseases
Dougall, W. C., & Chaisson, M. L. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 189
RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes
Armstrong, A. P., Miller, R. E., Jones, J. C., Zhang, J., Keller, E. T., & Dougall, W. C. (2007) · The Prostate · doi:10.1002/pros.20678 · Cited by 181
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédiní, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 177
Cathepsin K mRNA and Protein Expression in Prostate Cancer Progression
Brubaker, K. D., Rl, V., True, L. D., Thomas, R., & Corey, E. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.222 · Cited by 166
Self-citation
Control of RANKL gene expression
O’Brien, C. A. (2009) · Bone · doi:10.1016/j.bone.2009.08.050 · Cited by 170
Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis
Adekoya, T. O., & Richardson, R. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124449 · Cited by 160
Translational models of prostate cancer bone metastasis
Berish, R. B., Ali, A. N., Telmer, P. G., Ronald, J. A., & Leong, H. S. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0020-2 · Cited by 149
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi, K. S., Yang, J., Peleg, S., Sikes, C. R., Kreimann, E. L., Daliani, D., Olivé, M., Raymond, K. A., Janus, T. J., Logothetis, C. J., et al. (2003) · PubMed · Cited by 147
Calcium sensing receptor signalling in physiology and cancer
Brennan, S. C., Thiem, U., Roth, S., Aggarwal, A., Fetahu, I. S., Tennakoon, S., Gomes, A. R., Brandi, M. L., Bruggeman, F. J., Mentaverri, R., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.12.011 · Cited by 145
Eular Textbook on Rheumatic Diseases
Adwan, M. H. (2015) · Saudi Medical Journal · doi:10.15537/1658-3175.6383 · Cited by 141
Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis
Blair, J. M., Zhou, H., Seibel, M. J., & Dunstan, C. R. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0381 · Cited by 142
Notch Signaling and ERK Activation Are Important for the Osteomimetic Properties of Prostate Cancer Bone Metastatic Cell Lines
Zayzafoon, M., Abdulkadir, S. A., & McDonald, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308158200 · Cited by 137
Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells
Odero‐Marah, V., Wang, R., Chu, G. C., Zayzafoon, M., Xu, J., Shi, C., Marshall, F. F., Zhau, H. E., & Chung, L. W. K. (2008) · Cell Research · doi:10.1038/cr.2008.84 · Cited by 138
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials
Gdowski, A., Ranjan, A. P., & Vishwanatha, J. K. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0578-1 · Cited by 140
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 137
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 131
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 127
Role of osteoprotegerin (OPG) in cancer
Holen, I., & Shipman, C. M. (2006) · Clinical Science · doi:10.1042/cs20050175 · Cited by 119
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H., & Corey, E. (2001) · PubMed · Cited by 113
Self-citation
Markers of Bone Remodeling in Metastatic Bone Disease
Fohr, B., Dunstan, C. R., & Seibel, M. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030910 · Cited by 113
Osteoprotegerin in Prostate Cancer Bone Metastasis
Corey, E., Brown, L. G., Kiefer, J., Quinn, J. E., Pitts, T. E. M., Blair, J. M., & Vessella, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2033 · Cited by 115
Self-citation
The role of tumor microenvironment in prostate cancer bone metastasis
Morrissey, C. M., & Vessella, R. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21214 · Cited by 112
Self-citation
Prostate cancer expression of runt‐domain transcription factor Runx2, a key regulator of osteoblast differentiation and function
Brubaker, K. D., Vessella, R. L., Brown, L. G., & Corey, E. (2003) · The Prostate · doi:10.1002/pros.10233 · Cited by 107
Self-citation
The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma
Jimi, E., Furuta, H., Matsuo, K., Tominaga, K., Takahashi, T., & Nakanishi, O. (2010) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01781.x · Cited by 105
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
Mikami, S., Katsube, K., Oya, M., Ishida, M., Kosaka, T., Mizuno, R., Mochizuki, S., Ikeda, T., Mukai, M., & Okada, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2567 · Cited by 106
Bone morphogenetic protein signaling in prostate cancer cell lines
Brubaker, K. D., Corey, E., Brown, L. G., & Vessella, R. L. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10679 · Cited by 104
Self-citation
Osteoclast Signal Transduction During Bone Metastasis Formation
Győri, D., & Mócsai, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00507 · Cited by 107
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.12.2274 · Cited by 99
DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process.
Mori, K., Le Goff, B., Charrier, C., Battaglia, S., Heymann, D., & Rédini, F. (2007) · Bone · doi:10.1016/j.bone.2006.11.006 · Cited by 95
Effects of Ellagic Acid on Angiogenic Factors in Prostate Cancer Cells
Vanella, L., Giacomo, C. D., Acquaviva, R., Barbagallo, I. A., Volti, G. L., Cardile, V., Abraham, N. G., & Sorrenti, V. (2013) · Cancers · doi:10.3390/cancers5020726 · Cited by 93
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou, H., Kanomata, N., Goya, M., Kamijo, T., Yokose, T., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y., & Ochiai, A. (2003) · PubMed · Cited by 91
Shedding of RANKL by Tumor-Associated MT1-MMP Activates Src-Dependent Prostate Cancer Cell Migration
Sabbota, A. L., Kim, H.-R. C., Zhe, X., Fridman, R. A., Bonfil, R. D., & Cher, M. L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4416 · Cited by 88
Denosumab: A comprehensive review
Narayanan, P. (2013) · South Asian Journal of Cancer · doi:10.4103/2278-330x.119895 · Cited by 84
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
Antonarakis, E. S., Carducci, M. A., & Eisenberger, M. A. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.012 · Cited by 82
Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancer
Lu, T., Sathe, S. S., Swiatkowski, S. M., Hampole, C. V., & Stark, G. R. (2003) · Oncogene · doi:10.1038/sj.onc.1207332 · Cited by 80
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours
Poznak, C. H. V., Cross, S. S., Saggese, M., Hudis, C. A., Panageas, K. S., Norton, L., Coleman, R., & Holen, I. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.026534 · Cited by 79
Homing of Cancer Cells to the Bone
Mishra, A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0083-6 · Cited by 76
Modulation of prostate cancer growth in bone microenvironments
Edlund, M., Sung, S., & Chung, L. W. K. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10702 · Cited by 80
Prostate Cancer-Associated Membrane Type 1-Matrix Metalloproteinase
Bonfil, R. D., Dong, Z., Filho, J. C. T., Sabbota, A. L., Osenkowski, P., Nabha, S. M., Yamamoto, H., Chinni, S. R., Zhao, H., Mobashery, S., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060720 · Cited by 71
Self-citation
Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases
Huang, L., Cheng, Y. Y., Chow, L. T. C., Zheng, M. H., & Kumta, S. M. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.11.877 · Cited by 70
Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables
Cross, S. S., Harrison, R. F., Balasubramanian, S. P., Lippitt, J. M., Evans, C. A., Reed, M., & Holen, I. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.030031 · Cited by 63
Therapeutic potential of curcumin in prostate cancer—IV: Interference with the osteomimetic properties of hormone refractory C4‐2B prostate cancer cells
Dorai, T., Dutcher, J. P., Dempster, D. W., & Wiernik, P. H. (2003) · The Prostate · doi:10.1002/pros.10359 · Cited by 62
Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Sottnik, J. L., & Keller, E. T. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040012 · Cited by 61
Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors
Fili, S., Karalaki, M., & Schaller, B. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.011 · Cited by 63
Immune mediators in the tumor microenvironment of prostate cancer
Dai, J., Lü, Y., Roca, H., Keller, J. M., Zhang, J., McCauley, L. K., & Keller, E. T. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0198-3 · Cited by 60
Runx2 is expressed in human glioma cells and mediates the expression of galectin‐3
Vladimirova, V. A., Waha, A., Lückerath, K., Pesheva, P., & Probstmeier, R. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21686 · Cited by 58
Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses
Voorzanger‐Rousselot, N., & Garnero, P. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.008 · Cited by 59
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft
Kiefer, J., Vessella, R. L., Quinn, J. E., Ödman, A., Zhang, J., Keller, E. T., Kostenuik, P. J., Dunstan, C. R., & Corey, E. (2004) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-2869-0 · Cited by 57
Self-citation
Mechanisms governing bone metastasis in prostate cancer
Cher, M. L. (2001) · Current Opinion in Urology · doi:10.1097/00042307-200109000-00006 · Cited by 53
New targets for therapy in prostate cancer: modulation of stromal–epithelial interactions
Chung, L. W. K., Hsieh, C., Law, A., Sung, S., Gardner, T. A., Egawa, M., Matsubara, S., & Zhau, H. E. (2003) · Urology · doi:10.1016/s0090-4295(03)00796-9 · Cited by 56
Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2
Nadiminty, N., Lou, W., Lee, S. O., Mehraein‐Ghomi, F., Kirk, J. S., Conroy, J. M., Zhang, H., & Gao, A. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1849 · Cited by 54
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
Steger, G. G., & Bartsch, R. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011412656 · Cited by 57
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications
de Castro, J., García, R., Garrido, P., Isla, D., Massutí, B., Blanca, B., & Vázquez, J. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.06.004 · Cited by 53
Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma
Ito, R., Nakayama, H., Yoshida, K., Kuraoka, K., Motoshita, J., Oda, N., Oue, N., & Yasui, W. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0845-8 · Cited by 53
Expression of parathyroid hormone‐related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor‐κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas
Kumamoto, H., & Ooya, K. (2003) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2004.00204.x · Cited by 51
The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma
Jimi, E., Shin, M., FURUTA, H., Tada, Y., & Kusukawa, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1794 · Cited by 51
Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts
Tada, T., Jimi, E., Okamoto, M., Ozeki, S., & Okabe, K. (2005) · International Journal of Cancer · doi:10.1002/ijc.21008 · Cited by 50
RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Ando, K., Mori, K., Rédiní, F., & Heymann, D. (2008) · Current Drug Discovery Technologies · doi:10.2174/157016308785739857 · Cited by 54
Prostate cancer bone metastases biology and clinical management (Review)
Goode, E. A., Wang, N., & Munkley, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13749 · Cited by 49
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 49
Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer
Jung, K., Lein, M., von Hößlin, K., Brux, B., Schnorr, D., Loening, S. A., & Sinha, P. K. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.11.2061 · Cited by 48
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Yin, L., Hu, Q., & Hartmann, R. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713958 · Cited by 46
Epidermal Receptor Activator of NF-κB Ligand Controls Langerhans Cells Numbers and Proliferation,
Barbaroux, J.-B., Beleut, M., Brisken, C., Mueller, C. G., & Groves, R. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1103 · Cited by 43
The central role of osteoblasts in the metastasis of prostate cancer
Choueiri, M., Tu, S., Yu‐Lee, L., & Lin, S.-H. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9034-y · Cited by 43
Dysregulation of developmental pathways in bone metastasis
Sethi, N. S., & Kang, Y. (2010) · Bone · doi:10.1016/j.bone.2010.07.005 · Cited by 40
The hidden secrets of soluble RANKL in bone biology
Elango, J., Bao, B., & Wu, W. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155559 · Cited by 47
Serum Osteoprotegerin and Receptor Activator of Nuclear Factor-κ B Ligand as Indicators of Disturbed Osteoclastogenesis in Patients With Prostate Cancer
Jung, K., Stephan, C., Semjonow, A., Lein, M., Schnorr, D., & Loening, S. A. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000094191.39574.cb · Cited by 42
When prostate cancer meets bone: Control by wnts
Emami, K. H., & Corey, E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.040 · Cited by 42
Self-citation
Therapeutic implications of osteoprotegerin
Fili, S., Karalaki, M., & Schaller, B. J. (2009) · Cancer Cell International · doi:10.1186/1475-2867-9-26 · Cited by 43
In vivo real‐time imaging of TGF‐β‐induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer
Zhang, J., Lü, Y., Dai, J., Yao, Z., Kitazawa, R., Kitazawa, S., Zhao, X., Hall, D. E., Pienta, K. J., & Keller, E. T. (2003) · The Prostate · doi:10.1002/pros.20019 · Cited by 41
The Molecular Basis of Skeletal Metastases
Choong, P. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000093839.72468.da · Cited by 42
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 43
The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells
Shin, M., Matsuo, K., Tada, T., Fukushima, H., Furuta, H., Ozeki, S., Kadowaki, T., Yamamoto, K., Okamoto, M., & Jimi, E. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr198 · Cited by 36
Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma
Chuang, F., Hsue, S., Wu, C., & Chen, Y.-K. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00793.x · Cited by 40
Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
Morrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 36
Self-citation
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
Terpos, E., Efstathiou, E., Christoulas, D., Ρούσσου, Μ., Katodritou, E., & Dimopoulos, M. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902845610 · Cited by 36
Clinical Approaches to Osseous Metastases in Prostate Cancer
Morris, M. J., & Scher, H. I. (2003) · The Oncologist · doi:10.1634/theoncologist.8-2-161 · Cited by 35
Osteoprotegrin and the bone homing and colonization potential of breast cancer cells
Kapoor, P., Suva, L. J., Welch, D. R., & Donahue, H. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21382 · Cited by 37
Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint
Cardá, C., Silvestrini, G., de Ferraris, M. E. G., Peydró, A., & BONUCCI, E. (2005) · Tissue and Cell · doi:10.1016/j.tice.2005.03.002 · Cited by 35
Biology and clinical management of prostate cancer bone metastasis
Ye, X.-C. (2007) · Frontiers in bioscience · doi:10.2741/2311 · Cited by 35

Authors: Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L.
Affiliations: University of Washington (US)
American Red Cross (US)
Corresponding author: Brown, Julie M
ORCID: Brown, Julie M
Corey, Eva
True, Lawrence D
Yun, Theodore J
Venue: Urology
Publisher: Elsevier BV
Published: 2001-04
Volume: 57
Issue: 4
Pages: 611-616
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(00)01122-5
OpenAlex: W2114394594
Cited by: 234
References: 18
Citations by year: 2024: 1 · 2023: 5 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 9 · 2012: 14
FWCI: 5.82
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5p50dk047656-07)
National Institute of Diabetes and Digestive and Kidney Diseases (DK 47656-07)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords: osteoprotegerin, RANK ligand, prostate cancer, bone metastasis, bone resorption, bone remodeling, tumor stromal cells, luminal cells, bone turnover
MeSH terms: Aged, Aged, 80 and over, Base Sequence, Bone Neoplasms, Carrier Proteins, Glycoproteins, Humans, Immunohistochemistry, Lymphatic Metastasis, Male, Membrane Glycoproteins, Middle Aged, Prostate, Prostatic Neoplasms, RNA, Messenger, Cytokines, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoprotegerin and RANK ligand expression in prostate cancer.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks